Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal

Li Yang, Xiaoming Li, Yong Ji, Alison B. Kohan, David Q.H. Wang, Philip N. Howles, David Y. Hui, Jianghua Lai, Patrick Tso

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ezetimibe is a potent inhibitor of cholesterol absorption by enterocytes. Although ezetimibe minimally affects the absorption of triglyceride, it is unknown whether ezetimibe affects the secretion of the incretin hormones glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It has been shown that ezetimibe-treated mice are protected from diet-induced insulin resistance. Since GIP and GLP-1 promote the actions of insulin, we hypothesized that ezetimibe may affect the secretion of GIP and GLP-1 by enteroendocrine cells into lymph in response to the intestinal absorption of a mixed meal (Ensure). To test this hypothesis, we used the lymph fistula rat model to determine GIP and GLP-1 concentrations in lymph during the 2 h after the infusion of Ensure. Ezetimibe significantly reduced lymphatic cholesterol output during fasting, without coincident decreases in glucose, protein, and triglyceride outputs. However, ezetimibe did not influence cholesterol output after infusion of Ensure. Interestingly, ezetimibe significantly reduced the secretion of both GIP and GLP-1 into lymph after the infusion of Ensure. Therefore, the inhibitory effect of ezetimibe on GIP and GLP-1 secretion by enteroendocrine cells occurs outside of the effects of glucose, protein, or triglyceride secretion by the intestine.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume299
Issue number5
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Fingerprint

Incretins
Intestinal Absorption
Meals
Glucagon-Like Peptide 1
Lymph
Peptides
Enteroendocrine Cells
Triglycerides
Cholesterol
Anticholesteremic Agents
Ezetimibe
Glucose
Enterocytes
Fistula
Intestines
Insulin Resistance
Fasting
Proteins
Hormones
Insulin

Keywords

  • Cholesterol absorption
  • Glucagon-like peptide-1
  • Glucose-dependent insulinotropic polypeptide
  • Lymph

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Cite this

Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal. / Yang, Li; Li, Xiaoming; Ji, Yong; Kohan, Alison B.; Wang, David Q.H.; Howles, Philip N.; Hui, David Y.; Lai, Jianghua; Tso, Patrick.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 299, No. 5, 01.11.2010.

Research output: Contribution to journalArticle

Yang, Li ; Li, Xiaoming ; Ji, Yong ; Kohan, Alison B. ; Wang, David Q.H. ; Howles, Philip N. ; Hui, David Y. ; Lai, Jianghua ; Tso, Patrick. / Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2010 ; Vol. 299, No. 5.
@article{f2a8197baf7a4bb9b8d801b5353b1a61,
title = "Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal",
abstract = "Ezetimibe is a potent inhibitor of cholesterol absorption by enterocytes. Although ezetimibe minimally affects the absorption of triglyceride, it is unknown whether ezetimibe affects the secretion of the incretin hormones glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It has been shown that ezetimibe-treated mice are protected from diet-induced insulin resistance. Since GIP and GLP-1 promote the actions of insulin, we hypothesized that ezetimibe may affect the secretion of GIP and GLP-1 by enteroendocrine cells into lymph in response to the intestinal absorption of a mixed meal (Ensure). To test this hypothesis, we used the lymph fistula rat model to determine GIP and GLP-1 concentrations in lymph during the 2 h after the infusion of Ensure. Ezetimibe significantly reduced lymphatic cholesterol output during fasting, without coincident decreases in glucose, protein, and triglyceride outputs. However, ezetimibe did not influence cholesterol output after infusion of Ensure. Interestingly, ezetimibe significantly reduced the secretion of both GIP and GLP-1 into lymph after the infusion of Ensure. Therefore, the inhibitory effect of ezetimibe on GIP and GLP-1 secretion by enteroendocrine cells occurs outside of the effects of glucose, protein, or triglyceride secretion by the intestine.",
keywords = "Cholesterol absorption, Glucagon-like peptide-1, Glucose-dependent insulinotropic polypeptide, Lymph",
author = "Li Yang and Xiaoming Li and Yong Ji and Kohan, {Alison B.} and Wang, {David Q.H.} and Howles, {Philip N.} and Hui, {David Y.} and Jianghua Lai and Patrick Tso",
year = "2010",
month = "11",
day = "1",
doi = "10.1152/ajpgi.00294.2010",
language = "English (US)",
volume = "299",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal

AU - Yang, Li

AU - Li, Xiaoming

AU - Ji, Yong

AU - Kohan, Alison B.

AU - Wang, David Q.H.

AU - Howles, Philip N.

AU - Hui, David Y.

AU - Lai, Jianghua

AU - Tso, Patrick

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Ezetimibe is a potent inhibitor of cholesterol absorption by enterocytes. Although ezetimibe minimally affects the absorption of triglyceride, it is unknown whether ezetimibe affects the secretion of the incretin hormones glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It has been shown that ezetimibe-treated mice are protected from diet-induced insulin resistance. Since GIP and GLP-1 promote the actions of insulin, we hypothesized that ezetimibe may affect the secretion of GIP and GLP-1 by enteroendocrine cells into lymph in response to the intestinal absorption of a mixed meal (Ensure). To test this hypothesis, we used the lymph fistula rat model to determine GIP and GLP-1 concentrations in lymph during the 2 h after the infusion of Ensure. Ezetimibe significantly reduced lymphatic cholesterol output during fasting, without coincident decreases in glucose, protein, and triglyceride outputs. However, ezetimibe did not influence cholesterol output after infusion of Ensure. Interestingly, ezetimibe significantly reduced the secretion of both GIP and GLP-1 into lymph after the infusion of Ensure. Therefore, the inhibitory effect of ezetimibe on GIP and GLP-1 secretion by enteroendocrine cells occurs outside of the effects of glucose, protein, or triglyceride secretion by the intestine.

AB - Ezetimibe is a potent inhibitor of cholesterol absorption by enterocytes. Although ezetimibe minimally affects the absorption of triglyceride, it is unknown whether ezetimibe affects the secretion of the incretin hormones glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It has been shown that ezetimibe-treated mice are protected from diet-induced insulin resistance. Since GIP and GLP-1 promote the actions of insulin, we hypothesized that ezetimibe may affect the secretion of GIP and GLP-1 by enteroendocrine cells into lymph in response to the intestinal absorption of a mixed meal (Ensure). To test this hypothesis, we used the lymph fistula rat model to determine GIP and GLP-1 concentrations in lymph during the 2 h after the infusion of Ensure. Ezetimibe significantly reduced lymphatic cholesterol output during fasting, without coincident decreases in glucose, protein, and triglyceride outputs. However, ezetimibe did not influence cholesterol output after infusion of Ensure. Interestingly, ezetimibe significantly reduced the secretion of both GIP and GLP-1 into lymph after the infusion of Ensure. Therefore, the inhibitory effect of ezetimibe on GIP and GLP-1 secretion by enteroendocrine cells occurs outside of the effects of glucose, protein, or triglyceride secretion by the intestine.

KW - Cholesterol absorption

KW - Glucagon-like peptide-1

KW - Glucose-dependent insulinotropic polypeptide

KW - Lymph

UR - http://www.scopus.com/inward/record.url?scp=78149488801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149488801&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00294.2010

DO - 10.1152/ajpgi.00294.2010

M3 - Article

C2 - 20651007

AN - SCOPUS:78149488801

VL - 299

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5

ER -